Matthew Allaway, DO
Urology · Cumberland, MDNPI 1386750057
Payments from drug & device makers
What this record shows
This record is dominated by other: $20,592,418 of the $20,627,081 with a category attached, or 99.8%. Boston Scientific accounts for 100.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $20,624,190, more than ten times the $170 reported in 2019. Among urology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $122,780 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$20.6M
- AbbVie$639
- Pfizer$477
- Astellas Pharma US Inc$413
- Sumitomo Pharma America, Inc.$364
- Laborie Medical Technologies Corp.$223
- plus $996 from 19 others
What the payments were for
- Speaking & faculty fees$29,6500%
- Travel & lodging$1,4500%
- Food & beverage$3,3770%
- Education$1860%
- Other$20,592,418100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 20 | $20,623,970 |
| AbbVie(2 entities) | 35 | $639 |
| Pfizer | 25 | $477 |
| Astellas Pharma US Inc | 27 | $413 |
| Sumitomo Pharma America, Inc. | 17 | $364 |
| Laborie Medical Technologies Corp. | 5 | $223 |
| Medtronic | 5 | $184 |
| Teleflex LLC | 4 | $111 |
| Dendreon Pharmaceuticals LLC | 4 | $101 |
| Tolmar, Inc. | 3 | $84 |
| Axonics, Inc. | 4 | $83 |
| Koelis Inc. | 1 | $66 |
| Johnson & Johnson | 4 | $65 |
| Intuitive Surgical | 1 | $56 |
| Olympus America Inc. | 2 | $41 |
| Bioprotect Medical, Inc. | 1 | $33 |
| Neotract Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $28 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Calyxo, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $17 |
| 180 Medical, Inc. | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$20,592,559
- GENERAL ONCOLOGY$28,200
- GENERAL PELVIC ORGAN PROLAPSE$2,900
- Optilume BPH Drug Coated Balloon Catheter$175
How this compares
$20,627,081 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 29 | $409,052 |
| MyrbetriqMirabegron | 188 | $144,217 |
| Abiraterone Acetate | 15 | $109,432 |
| GemtesaVibegron | 89 | $71,579 |
| ElmironPentosan Polysulfate Sodium | 14 | $12,220 |
| Tamsulosin Hcl | 680 | $11,484 |
| Testosterone Cypionate | 156 | $8,538 |
| NitrofurantoinNitrofurantoin Macrocrystal | 223 | $6,396 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 205 | $5,908 |
| Oxybutynin Chloride ErOxybutynin Chloride | 212 | $5,357 |
| Testosterone | 47 | $5,216 |
| Potassium Citrate ErPotassium Citrate | 94 | $4,879 |
| Finasteride | 242 | $4,238 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,735 |
| Desmopressin Acetate | 50 | $2,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $413 | $553,269217 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $364 | $71,57989 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.
Other urology in Cumberland
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Laura GiustoOwings Mills$367K
- Amin HeratiBaltimore$160K
- Rian DicksteinHanover$144K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
- Brian MatlagaBaltimore$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.